博纳吐单抗治疗急性淋巴细胞白血病的研究进展

Research progress on blinatumomab in the treatment of acute lymphoblastic leukemia

近年来,随着免疫治疗和造血干细胞移植技术(hematopoietic stem cell transplantation,HSCT)的发展,急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)的缓解率逐渐升高,但复发难治性ALL的预后仍旧很差。博纳吐单抗(blinatumomab)作为一个新型的CD3和CD19双特异性抗体在复发难治性ALL中均获得较好的疗效,并于2014年12月被美国食品药品监督管理局(FDA)批准用于复发难治性急性B淋巴细胞白血病(B-cell acute lymphoblastic leukemia,B-ALL)的治疗。博纳吐单抗单药治疗初治ALL及联合化疗药物、酪氨酸激酶抑制剂治疗ALL均可改善患者生存期。本文主要围绕博纳吐单抗的临床试验、不良反应等方面的最新研究进行阐述。

The remission rate of acute lymphoblastic leukemia(ALL)has gradually increased with the progression of immunotherapy and hematopoietic stem cell transplantation(HSCT).While the prognosis of relapsed or refractory ALL is still poor,blinatumomab,a bispecific CD19/CD3 T-cell engager,has been approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia(B-ALL)because of its efficacy.A number of clinical trials have demonstrated the efficacy of this agent in the frontline setting and in combination regimens such as cytotoxic chemotherapy and tyrosine kinase inhibitor.In this paper,the clinical trials and adverse events of the latest research progress on blinatumomab are reviewed.